10-Q: Alkermes Reports Q1 2025 Financial Results, Impacted by Royalty Expiration and Manufacturing Revenue Changes

Alkermes' Q1 2025 net income from continuing operations decreased to $22.5 million, impacted by lower manufacturing and royalty revenues, partially offset by increased product sales and reduced operating expenses.

Summary

• Alkermes plc reported a net income from continuing operations of $22.5 million, or $0.14 per ordinary share basic and $0.13 per ordinary share diluted, for the three months ended March 31, 2025.
• This compares to a net income from continuing operations of $38.9 million, or $0.23 per ordinary share basic and $0.23 per ordinary share diluted, for the three months ended March 31, 2024.
• The decrease in net income was primarily due to a $54.8 million decrease in manufacturing and royalty revenue.
• This was partially offset by an $11.0 million increase in product sales, net, a $14.4 million decrease in operating expenses, an $8.0 million increase in other income, net, and a $4.9 million decrease in income tax provision.
• Product sales, net, increased to $244.5 million in Q1 2025 from $233.5 million in Q1 2024.
• Manufacturing and royalty revenues decreased to $62.0 million from $116.8 million.
• Research and development expenses increased to $71.8 million from $67.6 million.
• Selling, general, and administrative expenses decreased to $171.7 million from $179.7 million.
• The company's cash and investments totaled $916.2 million as of March 31, 2025.
• Alkermes expects its existing cash, cash equivalents, and investments will be sufficient to finance anticipated working capital and other cash requirements for at least the next twelve months.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue and income are down, the company is managing costs and has a strong cash position. The focus on pipeline development is a positive sign for the future.

Positives

• Product sales, net, increased by $11.0 million, driven by a 21% increase in LYBALVI unit sales and a 3% price increase across proprietary products.
• Selling, general, and administrative expenses decreased by $8.0 million, primarily due to lower media spending and professional service fees.
• The company generated $98.8 million in cash from operating activities during the quarter.
• Alkermes expects its existing cash, cash equivalents, and investments will be sufficient to finance anticipated working capital and other cash requirements for at least the next twelve months.

Negatives

• Manufacturing and royalty revenues decreased by $54.8 million, primarily due to the expiration of the INVEGA SUSTENNA royalty in the U.S. in August 2024.
• VIVITROL and ARISTADA/ARISTADA INITIO unit sales decreased by 5% and 9%, respectively.
• The decrease in net income from continuing operations during the three months ended March 31, 2025, as compared to the three months ended March 31, 2024, was primarily due to a decrease of $54.8 million in manufacturing and royalty revenue.

Risks

• Increased competition from new products or generic versions of the long-acting INVEGA products may lead to reduced unit sales and increased pricing pressure.
• Changes in global trade policies, including tariffs, could adversely affect the company's business, results of operations, or financial condition.
• The company is involved in litigation and other legal proceedings incidental to its normal business activities, including patent litigation related to VUMERITY and INVEGA TRINZA.
• The company has received a subpoena and civil investigative demands from U.S. state and federal governmental authorities for documents related to VIVITROL.

Future Outlook

Alkermes expects its existing cash, cash equivalents, and investments will be sufficient to finance its anticipated working capital and other cash requirements, including capital expenditures, for not less than twelve months following the date from which its financial statements were issued.

Industry Context

The report reflects the challenges faced by biopharmaceutical companies in maintaining revenue streams amid patent expirations and generic competition, while also highlighting the importance of pipeline development and strategic cost management.

Comparison to Industry Standards

• Alkermes' performance can be compared to companies like Teva, Mylan (now Viatris), and Sandoz, which also face challenges related to generic competition and patent expirations.
• The decrease in royalty revenue due to the INVEGA SUSTENNA patent expiration is a common issue in the pharmaceutical industry, similar to what companies like Pfizer and Eli Lilly have experienced with their blockbuster drugs.
• The company's focus on neuroscience and the development of innovative medicines aligns with the industry's trend towards specialized therapies and addressing unmet medical needs.
• The ALKS 2680 program, targeting narcolepsy and idiopathic hypersomnia, positions Alkermes in a growing market, comparable to Jazz Pharmaceuticals' focus on sleep disorders.
• The company's cash position and ability to finance operations for the next twelve months is a positive sign, similar to other well-managed biopharmaceutical companies.

Legal Proceedings

• Janssen Pharmaceutica's patent infringement lawsuit against Mylan Laboratories Limited regarding INVEGA TRINZA was affirmed by the U.S. Court of Appeals for the Federal Circuit on March 28, 2025.
• Biogen Inc. and Alkermes Pharma Ireland Limited filed a patent infringement lawsuit against Zydus Worldwide DMCC regarding VUMERITY, with a bench trial scheduled to begin on July 28, 2025.
• Acorda Therapeutics, Inc.'s appeal of the NY Southern District Court decision regarding the final arbitral award is scheduled for oral argument on June 6, 2025.
• Alkermes is involved in a product liability case alleging inadequate VIVITROL labeling and opioid overdose death.

Stakeholder Impact

• Shareholders may be concerned about the decrease in net income and royalty revenues.
• Employees in R&D may be affected by the focus on specific development programs like ALKS 2680.
• Customers and patients rely on Alkermes' products for the treatment of alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder.
• Suppliers may be impacted by changes in manufacturing volumes and sourcing decisions.
• Creditors are likely to view the company's strong cash position favorably.

Next Steps

• Continue development of ALKS 2680 with ongoing phase 2 clinical studies.
• Monitor and manage the impact of generic competition on the long-acting INVEGA products.
• Vigorously defend intellectual property in ongoing litigation, including the VUMERITY ANDA litigation with a bench trial scheduled for July 2025.
• Cooperate with governmental authorities in investigations related to VIVITROL.
• Monitor and adapt to changes in global trade policies and their potential impact on the business.

Key Dates

Keywords

Alkermes, financial results, Q1 2025, LYBALVI, VIVITROL, ARISTADA, manufacturing revenue, royalty revenue, ALKS 2680, INVEGA, VUMERITY